| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
HK:3692
Hansoh Pharmaceutical Group Company Limited
|
Aug 28, 2026 | BUY |
Strong Buy
+10.3% avg upside
5 analysts
|
$49.12
38.97% Upside
|
· | · |
|
HK:1801
Innovent Biologics
|
Aug 27, 2026 | BUY |
Strong Buy
+1.1% avg upside
7 analysts
|
$130.25
25.46% Upside
|
+0.0% | · |
|
HK:2269
Wuxi Biologics (Cayman)
|
Aug 27, 2026 | BUY |
Buy
-13.3% avg upside
4 analysts
|
$60.00
22.77% Upside
|
+0.0% | · |
|
HK:2268
WuXi XDC Cayman, Inc.
|
Aug 25, 2026 | BUY |
Buy
+9.6% avg upside
2 analysts
|
$93.00
32.97% Upside
|
-5.0% | · |
|
HK:1530
3SBio
|
Aug 24, 2026 | BUY |
Strong Buy
+78.8% avg upside
5 analysts
|
$34.78
115.83% Upside
|
-4.0% | · |
|
HK:2696
Shanghai Henlius Biotech, Inc. Class H
|
Aug 24, 2026 | BUY |
Strong Buy
+48.8% avg upside
2 analysts
|
$101.66
54.06% Upside
|
+5.1% | · |
|
HK:1093
CSPC Pharmaceutical Group
|
Aug 21, 2026 | BUY |
Strong Buy
+19.6% avg upside
7 analysts
|
$13.44
45.54% Upside
|
+1.4% | · |
|
HK:2506
Xunfei Healthcare Technology Co., Ltd.
|
Aug 20, 2026 | BUY |
Strong Buy
+38.6% avg upside
1 analyst
|
$99.58
38.57% Upside
|
-3.1% | · |
|
HK:6990
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
|
Aug 19, 2026 | BUY |
Strong Buy
+6.5% avg upside
3 analysts
|
$642.29
29.14% Upside
|
-3.5% | · |
|
HK:2367
Giant Biogene Holding Co. Ltd.
|
Aug 19, 2026 | BUY |
Strong Buy
+119.2% avg upside
3 analysts
|
$38.42
49.11% Upside
|
-9.5% | · |
|
ONC
BeOne Medicines
|
Aug 07, 2026 | BUY |
Strong Buy
-0.1% avg upside
28 analysts
|
$442.31
20.54% Upside
|
+7.9% | · |
|
PFE
Pfizer
|
Aug 07, 2026 | BUY |
Buy
+19.6% avg upside
45 analysts
|
$35.75
27.89% Upside
|
+4.5% | · |
|
TMO
Thermo Fisher
|
Jul 27, 2026 | BUY |
Strong Buy
-2.5% avg upside
38 analysts
|
$660.00
6.06% Upside
|
+12.7% | · |
|
HK:2637
Fujian Haixi Pharmaceuticals Co., Ltd. Class H
|
Jun 10, 2026 | BUY |
Strong Buy
+45.9% avg upside
1 analyst
|
$280.00
45.88% Upside
|
+9.8% | · |
|
HK:9969
InnoCare Pharma Ltd.
|
Apr 24, 2026 | BUY |
Strong Buy
+33.4% avg upside
3 analysts
|
$18.31
28.32% Upside
|
+5.8% | · |
|
HK:6699
Angelalign Technology Inc.
|
Mar 31, 2026 | BUY |
Buy
-7.2% avg upside
2 analysts
|
$91.89
2.15% Upside
|
+22.6% | · |
|
HK:1177
Sino Biopharmaceutical
|
Mar 30, 2026 | BUY |
Strong Buy
+43.8% avg upside
7 analysts
|
$8.70
59.70% Upside
|
-3.9% | · |
|
HK:9926
Akeso, Inc.
|
Mar 30, 2026 | BUY |
Strong Buy
+88.4% avg upside
3 analysts
|
$185.80
106.62% Upside
|
-26.8% | · |
|
HK:9606
Duality Biotherapeutics, Inc.
|
Mar 29, 2026 | BUY |
Strong Buy
+127.1% avg upside
2 analysts
|
$383.47
108.02% Upside
|
-30.5% | · |
|
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
|
Mar 12, 2026 | BUY |
Buy
+54.3% avg upside
2 analysts
|
$10.34
64.11% Upside
|
-5.9% | · |
|
HK:9887
Nanjing Leads Biolabs Co., Ltd. Class H
|
Sep 03, 2025 | BUY |
Strong Buy
+10.9% avg upside
1 analyst
|
$80.27
10.94% Upside
|
+18.9% | · |
|
HK:0013
HUTCHMED (China)
|
Aug 11, 2025 | BUY |
Buy
+502.2% avg upside
6 analysts
|
$31.39
62.05% Upside
|
-19.1% | · |
|
HK:2228
QuantumPharm, Inc.
|
Apr 03, 2025 | BUY |
Strong Buy
-0.5% avg upside
2 analysts
|
$7.57
1.75% Upside
|
+141.8% | · |
|
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
|
Mar 20, 2025 | BUY |
Strong Buy
-4.1% avg upside
1 analyst
|
$33.68
4.13% Downside
|
+12.7% | · |
|
HK:2522
Jiangxi Rimag Group Co., Ltd. Class H
|
Feb 27, 2025 | BUY |
Strong Buy
+896.1% avg upside
1 analyst
|
$52.39
896.07% Upside
|
-87.3% | · |
|
HK:9995
RemeGen Co. Ltd. Class H
|
Oct 31, 2024 | BUY |
Buy
-33.8% avg upside
2 analysts
|
$21.09
73.79% Downside
|
+366.3% | · |
|
HK:6127
JOINN Laboratories (China) Co., Ltd. Class H
|
Sep 02, 2024 | BUY |
Strong Buy
-60.8% avg upside
2 analysts
|
$8.57
65.06% Downside
|
+236.5% | · |
|
HK:1951
Jinxin Fertility Group Ltd.
|
Sep 02, 2024 | BUY |
Strong Buy
+52.1% avg upside
2 analysts
|
$3.33
49.94% Upside
|
+24.6% | · |
|
HK:1789
AK Medical Holdings Ltd.
|
Aug 30, 2024 | BUY |
Strong Buy
+38.8% avg upside
2 analysts
|
$5.27
3.31% Upside
|
+36.3% | · |
|
HK:9886
Dingdang Health Technology Group Ltd.
|
Jun 04, 2024 | BUY |
Strong Buy
+94.0% avg upside
1 analyst
|
$1.65
94.05% Upside
|
-57.8% | · |
|
HK:2325
Yunkang Group Limited
|
Apr 09, 2024 | BUY |
Strong Buy
+2296.6% avg upside
1 analyst
|
$13.78
2296.62% Upside
|
-69.7% | · |
|
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
|
Aug 29, 2023 | BUY |
Strong Buy
-60.4% avg upside
1 analyst
|
$22.36
60.38% Downside
|
-63.3% | · |
|
HK:1833
Ping An Healthcare and Technology Company
|
Aug 28, 2023 | BUY |
Buy
+271.0% avg upside
3 analysts
|
$23.80
270.98% Upside
|
-49.4% | · |
|
HK:9885
YSB Inc.
|
Aug 25, 2023 | BUY |
Strong Buy
+1530.7% avg upside
1 analyst
|
$57.97
1530.65% Upside
|
-85.2% | · |
|
HK:2096
Simcere Pharmaceutical Group Limited
|
Aug 23, 2023 | BUY |
Strong Buy
-26.6% avg upside
1 analyst
|
$8.15
26.56% Downside
|
-16.9% | · |
|
NBP
NovaBridge Biosciences
|
Aug 03, 2023 | HOLD |
Strong Buy
+1049.3% avg upside
14 analysts
|
— | -54.4% | · |
|
HK:2487
Cutia Therapeutics
|
Jul 24, 2023 | BUY |
Strong Buy
+1638.8% avg upside
1 analyst
|
$33.21
1638.81% Upside
|
-62.4% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.